Page 64 - Read Online

Page 32 of 33 Berardi et al. J Cancer Metastasis Treat 2019;5:79 I http://dx.doi.org/10.20517/2394-4722.2019.008

2008;7:45-50.
116. Ding XW, Yang WB, Gao S, Wang W, Li Z, et al. Prognostic significance of hERG1 expression in gastric cancer. Dig Dis Sci
2010;55:1004-10.
117. Crociani O, Lastraioli E, Boni L, Pillozzi S, Romoli MR, et al. hERG1 channels regulate VEGF-A secretion in human gastric cancer:
clinicopathological correlations and therapeutical implications. Clin Cancer Res 2014;20:1502-12.
118. Ma Y, Hou L, Yu F, Lu G, Qin S, et al. Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among
patients with non-small cell lung cancer. Oncotarget 2017;8:18417-23.
119. Viens P, Thyss A, Garnier G, Ayela P, Lagrange M, et al. GM-CSF treatment and hypokalemia. Ann Intern Med 1989;111:263.
120. Adams PC, Woodhouse KW, Adela M, Parnham A. Exaggerated hypokalaemia in acute myeloid leukaemia. Br Med J (Clin Res Ed)
1981;282:1034-5.
121. Stolinsky DC. Emergencies in oncology. Current management. West J Med 1978;129:169-76.
122. Bendlow J, Apps E, Jones LE, Poston GJ. Carcinoid syndrome. Eur J of Surg Oncol 2008;34:289-96.
123. Ikuta S, Yasui C, Kawanaka M, Aihara T, Yoshie H, et al. Watery diarrhea, hypokalemia and achlorhydria syndrome due to an adrenal
pheochromocytoma. World J Gastroenterol 2007;13:4649-52.
124. Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic
ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2001;970:134-44.
125. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, et al; Participants of the German Conn’s Registry. Cardiovascular and
cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin
Endocrinol Metab 2009;94:1125-30.
126. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, et al; Renal Insufficiency and Cancer Medications (IRMA) Study Group.
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and
anticancer medications (IRMA) study. Cancer 2007;110:1376-84.
127. Filippatos TD, Milionis HJ, Elisaf MS. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol
2005;75:449-60.
128. Yamamoto Y, Akashi Y, Minami T, Nozawa M, Kiba K, et al. Serious hypokalemia associated with abiraterone acetate in patients with
castration-resistant prostate cancer. Case Rep Urol 2018;2018:1414395.
129. Lim S. Approach to hypokalemia. Acta Med Indones 2007;39:56-64.
130. Kishimoto C, Tamaru K, Kuwahara H. Tall P waves associated with severe hypokalemia and combined electrolyte depletion. J
Electrocardiol 2014;47:93-4.
131. Viera AJ, Wouk N. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician 2015;92:487-95.
132. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, et al. Protective role of magnesium in the cardiovascular diseases: a review.
Mol Cell Biochem 2002;238:163-79.
133. Castro D, Sharma S. Hypokalemia. StatPearls Publishing; 2019.
134. Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. Arch Intern Med
1990;150:613-7.
135. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007;18:2649-52.
136. Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide
LAR during a 6-year period. Pancreas 2011;40:987-94.
137. Su H, Gu Y, Li F, Wang Q, Huang B, et al. The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism. PLoS
One 2013;8:e62399.
138. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a
consensus statement. J Clin Endocrinol Metab 2008;93:2454-62.
139. Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, et al. Targeted therapy-induced diarrhea: a review of the literature. Crit
Rev Oncol Hematol 2014;90:165-79.
140. Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 2000;160:1605-11.
141. Nagasaki A, Takamine W, Takasu N. Severe hyperkalemia associated with “alternative” nutritional cancer therapy. Clin Nutr 2005;24:864-5.
142. Metzner J, Evans JL, Domino KB. Life-threatening hyperkalemia during radiofrequency ablation of hepatocellular carcinoma. J Clin
Anesth 2010;22:473-6.
143. Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol 2016;777:78-87.
144. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med
2007;103:363-7.
145. Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour
lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010;149:578-86.
146. Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol 2002;56:95-101.
147. Bellevue R, Dosik H, Spergel G, Gussoff BD. Pseudohyperkalemia and extreme leukocytosis. J Lab Clin Med 1975;85:660-4.
148. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000;18:721-9.
149. Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron 2002;92:33-40.
150. Weisberg LS. Management of severe hyperkalemia. Crit Care Med 2008;36:3246-51.
151. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci 2014;347:93-100.
152. Ingram TC, Olsson JM. In brief: hypokalemia. Pediatr Rev 2008;29:e50-1.